BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34282215)

  • 1. Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.
    Yazdani M; Gholizadeh Z; Nikpoor AR; Mohamadian Roshan N; Jaafari MR; Badiee A
    Sci Rep; 2021 Jul; 11(1):14661. PubMed ID: 34282215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
    Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
    Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
    Zhang M; Yin T; Lu Y; Feng H
    Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
    Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
    Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma.
    Yazdani M; Gholizadeh Z; Nikpoor AR; Hatamipour M; Alani B; Nikzad H; Mohamadian Roshan N; Verdi J; Jaafari MR; Noureddini M; Badiee A
    Vaccine; 2020 Jul; 38(35):5665-5677. PubMed ID: 32653275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
    Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells.
    Alberca-Custodio RW; Faustino LD; Gomes E; Nunes FPB; de Siqueira MK; Labrada A; Almeida RR; Câmara NOS; da Fonseca DM; Russo M
    Front Immunol; 2020; 11():692. PubMed ID: 32391011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy.
    Yazdani M; Hatamipour M; Alani B; Nikzad H; Mohamadian Roshan N; Verdi J; Jaafari MR; Noureddini M; Badiee A
    Iran J Basic Med Sci; 2020 Aug; 23(8):1065-1077. PubMed ID: 32952954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
    Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
    J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
    Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
    Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach.
    Zhang X; Hu Q; He X; Cui X; Liang Z; Wang L; Deng X; Zhang Z; Sheng W; Han XD
    J Nanobiotechnology; 2023 May; 21(1):159. PubMed ID: 37208748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.